Type I atelocollagen with a 3D porous structure and pore diameter between 10-300µm
Comprises > 90% atelocollagen and < 10% glycosaminoglycan (GAG)
Dry form scaffold
Biodegraded in approximately 3 to 6 months
Myofibroblasts that are involved in the remodelling phase of wound healing migrate into the ologen™ CM scaffold, settle and adhere.
While a new collagen matrix is being produced by the Myofibroblasts, the ologen™ CM starts to degrade.
ologen™ CM degradation process continues and the scaffold is replaced by myofibroblast produced matrix.
Early bleb fibrosis (<1 month)
to
Late bleb fibrosis (1 month - 1 year)
to
at 12 months
Needling procedures
to
at 12 months
*n=39 (eye evaluated at 12 months) 1 **n=23 (eye evaluated at 12 months)1
References:
1. Rodríguez, José MN, et al. "Efficacy of the Ologen® collagen matrix in combination with the XEN® gel stent implantation in the treatment of openangle glaucoma: a case‐control study." Clinical & Experimental Ophthalmology (2020).
Suite 303, Highland House, 165 The Broadway, Wimbledon, SW19 1NE, UK
T: +44 (0)20 8944 7585.
General Enquiries:
[email protected]
Sale Enquiries:
[email protected]
Welcome to ProSys International Limited. We design, manufacture and market a wide range of UKCA and CE marked Medical Devices for a multitude of clinical specialities & applications. We are the exclusive UK & Ireland distributor for one of Europe’s leading manufacturers of medical devices, Dahlhausen.
LSAS001 Ethical Labour Standards PolicyISO 13485 Certificate